The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

The present invention provides a method of efficiently deprotecting a protected organic compound by catalytic hydrogenation. Specifically, the present invention provides a method of deprotecting an organic compound having at least one functional group selected from the group consisting of a carboxy group, an amino group and a hydroxy group, which is protected by a protecting group represented by the formula (I):
R.sup.1C(R.sup.2)(R.sup.3)-L.sup.1-(I)
[wherein R.sup.1 is an aryl group optionally having substituent(s), R.sup.2 and R.sup.3 are each independently, a hydrogen atom or an aryl group optionally having substituent(s), and L.sup.1 is a single bond, OCO or OCH.sub.2], comprising hydrogenation in the presence of a metal catalyst and halogenated acetic acid.

The present invention provides compounds of formula (I)

##STR00001## wherein X, L.sup.1 and R.sup.1 to R.sup.10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.

Fusion peptide comprising: i) an amino acid sequence as defined in SEQ ID No.: 1 or a related homolog having at least 90% identity with SEQ ID No.: 1 and having the ability of the sequence SEQ ID No.: 1 to inhibit the kinase-independent function of PI3K, and ii) a peptide having the ability to penetrate a cell.

Endomorphin-2 and tetrapeptide derivatives thereof are described. Pharmaceutical or cosmetic compositions containing endomorphin-2 or a tetrapeptide derivative thereof are therapeutically effective to treat, improve or prevent pain in human subjects, such as pain associated with a disorder, disease, condition, symptom, or syndrome of the nervous system, musculoskeletal system, vascular system, immune system, tumors or cancers, including, but not limited to, pain associated with arthritis, headache, muscles or joints upon topical or systemic administration.

Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.

Provided herein are Alanyl-Glutamine (Ala-GIn) formulations for use in treating and preventing side effects associated with cancer treatment. Also provided herein are methods of using the formulations provided herein to treat or prevent side effects associated with cancer treatment.

Provided herein are polypeptides containing stabilized therapeutic peptides related to enhancer of zeste homolog 2 (EZH2), histone lysine N-methyltransferase. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.

The present invention relates to a stapled peptide, a preparation method thereof and the use thereof, and more specifically to an amphipathic alpha-helical stapled peptide comprising hydrophobic amino acids and hydrophilic amino acids, a preparation method thereof, and the use thereof for intracellular delivery of an active substance.

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.